RATIONALE: Recent studies have shown that metabotropic glutamate receptor 5 (mGluR5) can modulate N-methyl-D-aspartate receptor function. Our previous findings demonstrated that the selective mGluR5 agonist (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) and the antagonist 2-methyl-6-(phenylethynyl)-pyridine can reduce and enhance the ketamine anesthesia, respectively. OBJECTIVE: The purpose of this study was to examine whether CHPG and positive allosteric modulator 3,3'-difluorobenzaldazine (DFB) can reverse ketamine-induced behavioral responses including locomotor hyperactivity, motor incoordination, sensorimotor gating deficit, and learning impairment. METHODS: Mice were pretreated with CHPG (5-50 nmol,) or DFB (40-100 nmol) followed by ketamine administration. Locomotor activity, rotarod test, prepulse inhibition (PPI) of acoustic startle test, and novel object recognition test were examined. RESULTS: CHPG and DFB had no effect on these behaviors when administered alone. Both of them attenuated the locomotor hyperactivity, motor incoordination, and cognitive impairment induced by ketamine. However, the ketamine-induced PPI deficit was reversed by CHPG (50 nmol) but not by DFB (up to 100 nmol). CHPG and DFB have distinct potency and efficacy in attenuating ketamine-induced behavioral response. CONCLUSIONS: These behavioral data extend previous findings and further suggest that positive modulation of mGluR5 may provide a novel approach for development of antipsychotic agents.
RATIONALE: Recent studies have shown that metabotropic glutamate receptor 5 (mGluR5) can modulate N-methyl-D-aspartate receptor function. Our previous findings demonstrated that the selective mGluR5 agonist (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) and the antagonist 2-methyl-6-(phenylethynyl)-pyridine can reduce and enhance the ketamine anesthesia, respectively. OBJECTIVE: The purpose of this study was to examine whether CHPG and positive allosteric modulator 3,3'-difluorobenzaldazine (DFB) can reverse ketamine-induced behavioral responses including locomotor hyperactivity, motor incoordination, sensorimotor gating deficit, and learning impairment. METHODS:Mice were pretreated with CHPG (5-50 nmol,) or DFB (40-100 nmol) followed by ketamine administration. Locomotor activity, rotarod test, prepulse inhibition (PPI) of acoustic startle test, and novel object recognition test were examined. RESULTS:CHPG and DFB had no effect on these behaviors when administered alone. Both of them attenuated the locomotor hyperactivity, motor incoordination, and cognitive impairment induced by ketamine. However, the ketamine-induced PPI deficit was reversed by CHPG (50 nmol) but not by DFB (up to 100 nmol). CHPG and DFB have distinct potency and efficacy in attenuating ketamine-induced behavioral response. CONCLUSIONS: These behavioral data extend previous findings and further suggest that positive modulation of mGluR5 may provide a novel approach for development of antipsychotic agents.
Authors: A K Malhotra; D A Pinals; C M Adler; I Elman; A Clifton; D Pickar; A Breier Journal: Neuropsychopharmacology Date: 1997-09 Impact factor: 7.853
Authors: A Pisani; P Gubellini; P Bonsi; F Conquet; B Picconi; D Centonze; G Bernardi; P Calabresi Journal: Neuroscience Date: 2001 Impact factor: 3.590
Authors: Gene G Kinney; Maryann Burno; Una C Campbell; Lisa M Hernandez; Dana Rodriguez; Linda J Bristow; P Jeffrey Conn Journal: J Pharmacol Exp Ther Date: 2003-03-26 Impact factor: 4.030
Authors: Craig W Lindsley; David D Wisnoski; William H Leister; Julie A O'brien; Wei Lemaire; David L Williams; Maryann Burno; Cyrille Sur; Gene G Kinney; Doug J Pettibone; Philip R Tiller; Sheri Smith; Mark E Duggan; George D Hartman; P Jeffrey Conn; Joel R Huff Journal: J Med Chem Date: 2004-11-18 Impact factor: 7.446
Authors: Julie A O'Brien; Wei Lemaire; Tsing-Bau Chen; Raymond S L Chang; Marlene A Jacobson; Sookhee N Ha; Craig W Lindsley; Hervé J Schaffhauser; Cyrille Sur; Douglas J Pettibone; P Jeffrey Conn; David L Williams Journal: Mol Pharmacol Date: 2003-09 Impact factor: 4.436
Authors: S W Fowler; A K Ramsey; J M Walker; P Serfozo; M F Olive; T R Schachtman; A Simonyi Journal: Neurobiol Learn Mem Date: 2010-11-17 Impact factor: 2.877
Authors: Summer L Thompson; Amanda C Welch; Julia Iourinets; Stephanie C Dulawa Journal: Psychopharmacology (Berl) Date: 2020-01-11 Impact factor: 4.530
Authors: María Luz Martín-Martín; José Manuel Bartolomé-Nebreda; Susana Conde-Ceide; Sergio A Alonso de Diego; Silvia López; Carlos M Martínez-Viturro; Han Min Tong; Hilde Lavreysen; Gregor J Macdonald; Thomas Steckler; Claire Mackie; Thomas M Bridges; J Scott Daniels; Colleen M Niswender; Meredith J Noetzel; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer Journal: Bioorg Med Chem Lett Date: 2015-01-28 Impact factor: 2.823
Authors: Jennifer E Ayala; Yelin Chen; Jessica L Banko; Douglas J Sheffler; Richard Williams; Alexandra N Telk; Noreen L Watson; Zixiu Xiang; Yongqin Zhang; Paulianda J Jones; Craig W Lindsley; M Foster Olive; P Jeffrey Conn Journal: Neuropsychopharmacology Date: 2009-03-18 Impact factor: 7.853